Related Experiment Video
Updated: Mar 10, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Prediction of atorvastatin plasmatic concentrations in healthy volunteers using integrated pharmacogenetics
Omar Fernando Cruz-Correa1, Rafael Baltazar Reyes León-Cachón2,3, Hugo Alberto Barrera-Saldaña2,4
1Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Col. Arenal Tepepan, Delegación Tlalpan, México, D.F. C.P. 14610, Mexico.
Aim:
To use variants found by next-generation sequencing to predict atorvastatin plasmatic concentration profiles (AUC) in healthy volunteers.
Subjects & Methods:
A total of 60 healthy Mexican volunteers were enrolled in this study. We used variants with a predicted functional effect across 20 genes involved in atorvastatin metabolism to construct a regression model using a support vector approach with a radial basis function kernel to predict AUC refining it afterwards in order to explain a greater extent of the variance.
Results:
The final support vector regression model using 60 variants (including six novel variants) explained 94.52% of the variance in atorvastatin AUC.
Conclusion:
An integrated analysis of several genes known to intervene in the different steps of metabolism is required to predict atorvastatin's AUC.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics and Pharmacogenomics: Overview

